Missing Script

Get updates

MS-N129 · Supportive care · Human evidence · Appraised 25 October 2026

Can a handheld fan directed toward the face ease breathlessness in people with advanced cancer?

Evidence at a glance

  • Evidence label: Supported option for short-term symptom relief; it does not treat the cause of breathlessness
  • Benefit: Small randomized trials and a 2026 meta-analysis support an immediate reduction in perceived breathlessness for some people.
  • Certainty: Moderate for an immediate subjective effect, but lower for sustained benefit because trials are small and heterogeneous.
  • Risk: Usually low, but a fan must not delay assessment of new or rapidly worsening breathlessness, low oxygen, infection, a blood clot or fluid around the lung.

What was studied

Population and design: A 2025 randomized crossover trial enrolled 36 nonhypoxemic people with incurable cancer; 28 completed both 30-minute periods of fan therapy and high-flow nasal air. Earlier randomized cancer trials compared airflow to the face with airflow to the legs or usual care.

Studied regimen: A small handheld fan was aimed across the face for short sessions. This is an airflow intervention, not oxygen therapy and not a treatment for the cancer or lung disease causing breathlessness.

What the evidence found

In the crossover trial, median breathlessness on a 0–10 scale fell from 5.0 to 2.5 after fan therapy. The median change was about one point and did not differ from high-flow nasal air; no significant adverse events were reported.

A 2026 meta-analysis of 12 randomized trials (463 adults with advanced cancer, COPD, interstitial lung disease or heart failure) found an immediate benefit (standardized mean difference −1.33, 95% CI −2.12 to −0.53), but heterogeneity was very high (I²=91%). Repeated short-term use did not show a clear cumulative benefit, and oxygen saturation and breathing rate did not improve.

How to interpret it

The useful signal is immediate symptom relief, not improved oxygenation or disease control. Effects vary, and the pooled estimate mixes several diseases and fan protocols. ASCO guidance recommends airflow directed at the cheek as a nonpharmacologic option while the underlying cause is assessed and treated.

Practical safety context

Stop if airflow feels distressing or dries the eyes. A new or sudden breathing change, chest pain, blue lips, confusion, fever, coughing blood or fainting needs urgent assessment. Supplemental oxygen is for documented hypoxemia; a fan is not a substitute.

Questions for the care team

  • What is causing the breathlessness, and does it need urgent treatment?
  • Is oxygen saturation low, or is airflow being used for comfort despite normal oxygen?
  • What change on a 0–10 breathlessness scale would count as worthwhile?

Funding and conflicts

The crossover trial was registered as NCT05257850. Funding and conflict details were not verified from the abstract available in this appraisal; the review and guideline should not be counted as additional independent trials.

Sources

Last literature search: 25 October 2026. Record appraisal: 25 October 2026. This page is educational and does not replace individualized medical advice. Symptom or function improvement must not be interpreted as evidence of tumor response, delayed recurrence or longer survival.